Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5202219
Max Phase: Preclinical
Molecular Formula: C26H18ClF2N3O2S2
Molecular Weight: 542.03
Associated Items:
ID: ALA5202219
Max Phase: Preclinical
Molecular Formula: C26H18ClF2N3O2S2
Molecular Weight: 542.03
Associated Items:
Canonical SMILES: O=C1NC(c2ccsc2)(c2cccc(Nc3ccc(F)c(F)c3)n2)CC(O)=C1Sc1ccccc1Cl
Standard InChI: InChI=1S/C26H18ClF2N3O2S2/c27-17-4-1-2-5-21(17)36-24-20(33)13-26(32-25(24)34,15-10-11-35-14-15)22-6-3-7-23(31-22)30-16-8-9-18(28)19(29)12-16/h1-12,14,33H,13H2,(H,30,31)(H,32,34)
Standard InChI Key: MREKVQUMZPMFFT-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 542.03 | Molecular Weight (Monoisotopic): 541.0497 | AlogP: 7.14 | #Rotatable Bonds: 6 |
Polar Surface Area: 74.25 | Molecular Species: ACID | HBA: 6 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 5 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 5.80 | CX Basic pKa: 4.18 | CX LogP: 5.75 | CX LogD: 4.26 |
Aromatic Rings: 4 | Heavy Atoms: 36 | QED Weighted: 0.24 | Np Likeness Score: -1.57 |
1. Wei B, Robarge K, Labadie SS, Chen J, Corson LB, DiPasquale A, Dragovich PS, Eigenbrot C, Evangelista M, Fauber BP, Hitz A, Hong R, Lai KW, Liu W, Ma S, Malek S, O'Brien T, Pang J, Peterson D, Salphati L, Sampath D, Sideris S, Ultsch M, Xu Z, Yen I, Yu D, Yue Q, Zhou A, Purkey HE.. (2022) Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase., 59 [PMID:35065235] [10.1016/j.bmcl.2022.128576] |
2. Wei B, Robarge K, Labadie SS, Chen J, Corson LB, DiPasquale A, Dragovich PS, Eigenbrot C, Evangelista M, Fauber BP, Hitz A, Hong R, Lai KW, Liu W, Ma S, Malek S, O'Brien T, Pang J, Peterson D, Salphati L, Sampath D, Sideris S, Ultsch M, Xu Z, Yen I, Yu D, Yue Q, Zhou A, Purkey HE.. (2022) Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase., 59 [PMID:35065235] [10.1016/j.bmcl.2022.128576] |
Source(1):